Soleus Capital Management’s RxSight RXST Stock Holding History

Soleus Capital Management’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-80,000	Closed	-$1.33M	–	107
2023 Q1	$1.33M	Buy	+80,000	New	+$1.13M	0.14%	69

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Soleus Capital Management's RXST Position: Q2 2023 in Review

Soleus Capital Management sold out of RxSight (RXST) in Q2 2023, closing a stake of 80,000 shares — an estimated $1.33M sold.

Soleus Capital Management first reported a position in RXST in Q1 2023 and held it in 1 quarter. The position peaked at $1.33M in Q1 2023. 115 funds tracked by Wall St. Rank hold RXST as of Q2 2023.

Soleus Capital Management reported no remaining RxSight position as of Q2 2023 after selling out during the quarter.
Soleus Capital Management sold 80,000 RxSight shares in Q2 2023, an estimated $1.33M.
Soleus Capital Management first reported a position in RxSight in Q1 2023 and held it in 1 quarter.
Soleus Capital Management's RxSight position peaked at $1.33M in Q1 2023.
115 funds tracked by Wall St. Rank held RxSight as of Q2 2023.

Based on Soleus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.